C-Reactive Protein Is a Possible Marker Relative to severity and mortality of COVID-19 Infection
Gastroenterology and Hepatology from Bed to Bench,
30 December 2021
Introduction: COVID-19 pandemic changed life style of human in recent years and appeared as a complicated health problem. Clinical finding indicates to mild, sever, and fatal condition of this disease. Prediction of disease severity is a significant point in managing COVID-19 infection. In the present study it is tried to introduce possible biomarker to differentiate the sever and fatal condition of disease.
Methods: Number of 195 differentially genes that discriminate the fatal patients from the patient with sever condition were extracted from literature and screen to find the significant differentially genes (DEGs). The significant DEGs plus added 90 first neighbors from STRING database were included in interactome by using Cytoscape software v 3.7.2. The central nodes of the analyzed network were identified and assessed.
Results: Number of 10 significant DEGs were candidate to be assessed which 9 individuals were recognized by STRING database. IL6, ALB, TNF, CRP, INS, MPO, C3, CXCL8, TTR, and TLR4 were determined as central nodes. IL6, CRP, and TTR are highlighted as the critical genes related to severity of COVID-19 infection.
Conclusion: CRP was pointed as the best possible biomarker which its levels are related to the severity and fatality of COVID-19 infection.
- C-reactive protein; COVID-19; Bioinformatics; Severity; Network analysis
2. Pietromonaco PR, Overall NC. Applying relationship science to evaluate how the COVID-19 pandemic may impact couples’ relationships. American Psychologist. 2020.
3. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir–a potential treatment in the COVID-19 pandemic? Journal of virus eradication. 2020;6(2):45-51.
4. Obi AT, Barnes GD, Wakefield TW, Brown S, Eliason JL, Arndt E, et al. Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2020;8(4):526-34.
5. Cirrincione L, Plescia F, Ledda C, Rapisarda V, Martorana D, Moldovan RE, et al. COVID-19 pandemic: prevention and protection measures to be adopted at the workplace. Sustainability. 2020;12(9):3603.
6. Zhang Y, Ren J. ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications. Pharmacology & therapeutics. 2011;132(1):86-95.
7. Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World journal of gastroenterology. 2016;22(42):9300.
8. Churko JM, Mantalas GL, Snyder MP, Wu JC. Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. Circulation research. 2013;112(12):1613-23.
9. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nature medicine. 2004;10(11):1177-85.
10. Barbosa EB, Vidotto A, Polachini GM, Henrique T, Marqui ABTd, Tajara EH. Proteomics: methodologies and applications to the study of human diseases. Revista da Associacao Medica Brasileira. 2012;58(3):366-75.
11. Guingab-Cagmat J, Cagmat E, Hayes RL, Anagli J. Integration of proteomics, bioinformatics, and systems biology in traumatic brain injury biomarker discovery. Frontiers in neurology. 2013;4:61.
12. Wu X, Al Hasan M, Chen JY. Pathway and network analysis in proteomics. Journal of theoretical biology. 2014;362:44-52.
13. Santiago JA, Potashkin JA. Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PloS one. 2013;8(12):e83940.
14. Özgür A, Vu T, Erkan G, Radev DR. Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics. 2008;24(13):i277-i85.
15. Sadria M, Karimi S, Layton AT. Network centrality analysis of eye-gaze data in autism spectrum disorder. Computers in biology and medicine. 2019;111:103332.
16. Wang M, Huang J, Liu M, Zhang D, editors. Functional connectivity network analysis with discriminative hub detection for brain disease identification. Proceedings of the AAAI Conference on Artificial Intelligence; 2019.
17. Pavel A, Del Giudice G, Federico A, Di Lieto A, Kinaret PA, Serra A, et al. Integrated network analysis reveals new genes suggesting COVID-19 chronic effects and treatment. Briefings in bioinformatics. 2021;22(2):1430-41.
18. Rezaei-Tavirani M, Nejad MR, Arjmand B, Tavirani SR, Razzaghi M, Mansouri V. Fibrinogen Dysregulation is a Prominent Process in Fatal Conditions of COVID-19 Infection; a Proteomic Analysis. Archives of Academic Emergency Medicine. 2021;9(1):e26-e.
19. Shu T, Ning W, Wu D, Xu J, Han Q, Huang M, et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity. 2020;53(5):1108-22. e5.
20. Wang L. C-reactive protein levels in the early stage of COVID-19. Medecine et maladies infectieuses. 2020;50(4):332-4.
21. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Annals of clinical microbiology and antimicrobials. 2020;19:1-7.
22. Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections. The American journal of tropical medicine and hygiene. 2020;103(2):561-3.
23. Acar E, Demir A, Yıldırım B, Kaya MG, Gökçek K. The role of hemogram parameters and CRP in predicting mortality in COVID‐19 infection. International journal of clinical practice. 2021:e14256.
24. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Medecine et maladies infectieuses. 2020.
25. Zhang H, Wang X, Fu Z, Luo M, Zhang Z, Zhang K, et al. Potential factors for prediction of disease severity of COVID-19 patients. MedRxiv. 2020.
26. Lopez-Castaneda S, García-Larragoiti N, Cano-Mendez A, Blancas-Ayala K, Damian-Vázquez G, Perez-Medina AI, et al. Inflammatory and Prothrombotic Biomarkers Associated With the Severity of COVID-19 Infection. Clinical and Applied Thrombosis/Hemostasis. 2021;27:1076029621999099.
27. Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain, behavior, and immunity. 2021;94:138-47.
28. Vassiliou AG, Keskinidou C, Jahaj E, Gallos P, Dimopoulou I, Kotanidou A, et al. ICU admission levels of endothelial biomarkers as predictors of mortality in critically ill COVID-19 patients. Cells. 2021;10(1):186.
- Abstract Viewed: 0 times